Lilly’s Retevmo receives FDA approval to treat solid tumours

Lilly’s Retevmo receives FDA approval to treat solid tumours

Submitted by admin on September 22, 2022 - 10:13am
Source: 
Pharmaceutical Business Review
News Tags: 
Eli Lilly
FDA
Retevmo
solid tumors
metastatic solid tumors
Headline: 
Lilly’s Retevmo receives FDA approval to treat solid tumours
snippet: 

Eli Lilly and Company (Lilly) has received the US Food and Drug Administration (FDA) approval for its RET kinase inhibitor, Retevmo (selpercatinib), to treat advanced or metastatic solid tumours in adult patients.

Do Not Allow Advertisers to Use My Personal information